Literature DB >> 14576340

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

Johan W Jonker1, Alfred H Schinkel.   

Abstract

For the elimination of environmental toxins and metabolic waste products, the body is equipped with a range of broad-specificity transporters that are generally present in the liver, kidney, and intestine. The polyspecific organic cation transporters OCT1, 2, and 3 (SLC22A1-3) mediate the facilitated transport of a variety of structurally diverse organic cations, including many drugs, toxins, and endogenous compounds. OCT1 and OCT2 are found in the basolateral membrane of hepatocytes, enterocytes, and renal proximal tubular cells. OCT3 has a more widespread tissue distribution and is considered to be the major component of the extraneuronal monoamine transport system (or uptake-2), which is responsible for the peripheral elimination of monoamine neurotransmitters. Studies with knockout mouse models have directly demonstrated that these transporters can have a major impact on the pharmacological behavior of various substrate organic cations. The recent identification of polymorphic genetic variants of human OCT1 and OCT2 that severely affect transport activity thus suggests that some of the interpatient differences in response and sensitivity to cationic drugs may be caused by variable activity of these transporters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576340     DOI: 10.1124/jpet.103.053298

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  111 in total

1.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

2.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Authors:  Meindert Danhof; Gunnar Alvan; Svein G Dahl; Jochen Kuhlmann; Gilles Paintaud
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

Review 4.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

Review 5.  Genetic variation in drug transporters in ethnic populations.

Authors:  C D Cropp; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2008-06-04       Impact factor: 6.875

Review 6.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion.

Authors:  Tammy L Sirich; Benjamin A Funk; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

8.  Functional organic cation transporters mediate osteogenic response to metformin in human umbilical cord mesenchymal stromal cells.

Authors:  Faisal E Al Jofi; Tao Ma; Dong Guo; Monica P Schneider; Yan Shu; Hockin H K Xu; Abraham Schneider
Journal:  Cytotherapy       Date:  2018-03-16       Impact factor: 5.414

Review 9.  Renal effects of novel antiretroviral drugs.

Authors:  James Milburn; Rachael Jones; Jeremy B Levy
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

10.  Protein kinase inhibition differentially regulates organic cation transport.

Authors:  Alexander M Gerlyand; Daniel S Sitar
Journal:  Can J Physiol Pharmacol       Date:  2009-10       Impact factor: 2.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.